In just a few years, China has gone from having no approved CAR-T therapies to hosting one of the world's most active CAR-T approval landscapes. For international patients, that means more options, shorter waits at high-volume centers, and costs well below those in the US or Europe.
The First Approval: A Milestone in 2021
China's first approved CAR-T product — 奕凯达 (Yescarta® / 阿基仑赛), a CD19-targeted therapy from Fosun Kite — was approved by the NMPA in 2021 for relapsed/refractory large B-cell lymphoma. Later that same year, a second CD19 product, 倍诺达 (Carteyva® / 瑞基奥仑赛) from JW Therapeutics, followed. Together they established CAR-T as a reachable option within China's healthcare system.
Expanding Beyond CD19
The next wave broadened the menu. BCMA-targeted CAR-T products for relapsed/refractory multiple myeloma reached the Chinese market, including domestically developed options such as 福可苏 (Equecabtagene / 伊基奥仑赛, Innovent / IASO Bio) and 赛凯泽 (Zevorcabtagene / 泽沃基奥仑赛, Carsgen). A CD19 product for relapsed/refractory B-cell acute lymphoblastic leukemia, 源瑞达 (Inaticabtagene / 纳基奥仑赛, Juven Sc), also joined the list. By 2024–2025 the count of NMPA-approved CAR-T products had grown beyond five, and more are in late-stage development.
Two Targets, Two Disease Families
CD19 CAR-Ts address B-cell cancers — leukemias and lymphomas. BCMA CAR-Ts address multiple myeloma. The target determines which disease a product can treat; the approved indication determines the specific, usually relapsed/refractory, setting.
Why It Matters for International Patients
Three factors make China an attractive destination for CAR-T:
- Experience at scale. Leading centers run active cellular-therapy programs and manage CRS/ICANS routinely.
- Shorter waits. High manufacturing volume means less delay between apheresis and infusion than in some other regions.
- Cost. List prices and total treatment episodes are typically a fraction of US/European pricing, with growing local insurance coverage.
A Rapidly Moving Field
The pipeline keeps growing — new targets (such as GPRC5D for myeloma), allogeneic "off-the-shelf" approaches, and solid-tumor programs are all advancing. Which product and indication are actually available to a given patient depends on the treating hospital and current approvals.